NASDAQ · LVTX
LAVA Therapeutics N.V.
$1.74-$0.07 (-3.87%)
LAVA Therapeutics N.V.’s quoted price sits in the upper half of its reported 52-week range, 13.0% below the high.
Loading market information…
NASDAQ · CPIX · USD
Stock price, earnings
Quote as of Oct 30, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cumberland Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.46% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cumberland Pharmaceuticals Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$0.13. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cumberland Pharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:46 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 6, 2025 |
| $0.16+1,700.0% vs estimate |
| $11.71M-3.84% vs estimate |
| Q4 2024 | Mar 4, 2025 | -$0.02+81.82% vs estimate | $10.44M+13.5% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.02+84.62% vs estimate | $9.09M+6.01% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.74-$0.07 (-3.87%)
LAVA Therapeutics N.V.’s quoted price sits in the upper half of its reported 52-week range, 13.0% below the high.
$7.07-$0.24 (-3.28%)
Rockwell Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.19% below the high.
$1.00-$0.04 (-3.85%)
ABVC BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.32% below the high.
$0.80-$0.05 (-5.79%)
Celularity Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.62% below the high.
$2.38-$0.06 (-2.46%)
Quantum BioPharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 80.9% below the high.
$0.38+$0.02 (+5.32%)
Dyadic International, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.24% below the high.
$0.66-$0.07 (-9.6%)
Lantern Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.77% below the high.
$1.46-$0.29 (-16.57%)
CalciMedica, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.94% below the high.
